Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.

Clin Pharmacokinet. Accepted.

Zhao X

Cui YM

5.053

Metformin versus insulin for gestational diabetes mellitus: a meta-analysis.

 Br J Clin Pharmacol.
2015 Apr 29. 
 [Epub ahead of print]

Zhao LP

Zhou Y

3.878

Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations.

J Clin Pharm Ther.
2015;40(4):404-8.

Zhou Y

Cui YM

1.668

Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.

Clin Ther. 2015;37(7):1493-1502.

Zhao X

Cui YM

2.731

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.

Eur J Clin Pharmacol.
2015 Aug 19.

Yang T

Cui Y

2.966

Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.

JAMA.
2015 Apr 7;313(13):1325-35.

Huo Y

-

35.289

Folic acid supplementation with and without vitamin B6 and revascularization risk: a meta-analysis of randomized controlled trials.

Clin Nutr.
2014 Aug;33(4):603-12.

Qin X

Huo Y

4.476

Population pharmacokinetic study of cyclosporine in the hematopoietic stem cell transplant recipients.

Int J Clin Pharmacol Ther. 2013 Jul;51(7):568-75.

Zhou Y

Cui YM

1.044

Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics.

Pharmacogenomics. 2013 Jul;14(10):1179-89.

Xiang Q

Cui YM

3.425

Folic acid supplementation and cancer risk: A meta-analysis of randomized controlled trials.

Int J Cancer.
2013 Sep 1;133(5):1033-41.

Qin X

Huo Y

5.007

Pharmacokinetics, safety, and tolerability of exenatide once weekly in Chinese patients with type 2 diabetes mellitus.

J Diabetes. 2013 ;5(2):127-35.

Cui YM

Guo XH

2.349

Integration of genetic and clinical data to analyze pharmacokinetic profile of mycophenolic acid in a population of Chinese patients with glomerular disease.

Int. Res. J. Pharm. Pharmacol.
2013; 3(2): 19-28.

Xiang Q,
Yu F

Cui YM
Wang HY

1.323

The Influence of UGT 2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers.

Drug Metab Pharmacokinet.
2013;28(3):239-43.

Wang ZN, Xiang Q

Cui YM

2.863

Factors underlying the association of body mass index with serum ALT in Chinese hypertensive adults without known hepatic diseases.

J Zhejiang Univ Sci B.
2013 Aug; 14(8): 743–748.

Zhang Y

Huo Y

1.293

The influence of MDR1 G2677T/A genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.

Pharmacology, 2012;89:105-110.

Xiang Q

Cui YM

1.603

MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults.

Nutr J.
2012; 11-2.

Qin X

Huo Y

4.196

Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?

Pharmacogenet Genomics. 2012;22(6):421-8.

Qin X

Huo Y

3.608

Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects.

Acta Pharmacol Sin. 2012; 33(11):1395-1400.

Wang ZN

Cui YM

2.354

Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Acta Pharmacol Sin. 2012; 33(11):1387-94.

Zhang DM

Cui YM

2.354

A single-center, randomized, open-label, dose-escalation study to evaluate the pharmacokinetics of tacrine analogue octahydrogenacridine succinate tablets in healthy Chinese subjects.

Biol Pharm Bull. 2012;35(9):1502-8.

Zhao X

Cui YM

1.849

Effect of folic acid intervention on ALT concentration in hypertensives without known hepatic disease: a randomized, double-blind, controlled trial.

Eur J Clin Nutr. 2012;66(5):541-8.

Qin X

Huo Y

2.756

Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects.

Biol Pharm Bull. 2011; 34: 1841-1848.

Zhang DM

Cui YM

1.657

Safety and Pharmacokinetic Studies of Silodosin, a New α1A-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects.

Biol Pharm Bull, 2011, 34, 1240-1245.

Zhou Y

Cui YM

1.657

Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers.

Acta Pharmacol Sin. 2011;32(12):1549-54.

Sun PH

Cui YM

1.953

Effect of CYP2D6, CYP3A5 and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and its Active Moiety.

J Clin Pharmacol. 2010;50:659-66.

Xiang Q

Cui YM

3.063

Safety, pharmacokinetics and pharmacodynamics of single and multiple dose of rivaroxaban – an oral, direct Factor Xa inhibitor – in healthy Chinese subjects.

Br J Clin Pharmacol.
2009; 66: 77-88.

Zhao X

Cui YM

3.246

Determination of silodosin in human plasma by liquid chromatography-tandem mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 3724-3728.

Zhao X

Cui YM

2.777

Exenatide pharmacokinetics in healthy Chinese subjects.

International Journal of clinical pharmacology and therapeutics.
2008, 46, 459-465.

Zhao X

Cui YM

3.128

Atomoxetine Pharmacokinetics in Healthy Chinese Subjects and effect of the CYP2D6*10 allele.

Br J Clin Pharmacol. 2007;64:445-9.

Cui YM

Cui YM

2.681

Liquid chromatography tandem mass spectrometry assay to determine the pharmacokinetics of aildenafil in human plasma.

J Pharm Biomed Anal. 2007;44:231-5.

Wang J

Cui YM

2.761